The ROVI Granada Team armed themselves with helmets and bicycles to tackle last Saturday’s bike ride with the Fundación Deporte y Desafío. During the 16-kilometre ride, the 15 ROVI volunteers were able to accompany the members of the foundation on their way to the adventure, completing the La Laguna route while enjoying the good weather and the views that accompanied them.
The starting point of the route was the Aura de la Naturaleza El Aguadero, where the volunteers were able to take the bikes provided by the foundation and set off. From there, a circular route awaited them, passing by the Ermita de la Virgen de la Cabeza (Cozvijar, Granada) and then continuing on to the Cascada del Río Dúrcal. A route with a low gradient and accessible to all participants.
Say goodbye to Diverclick. The new ROVI Discounts platform will bring more and better offers for ROVI employees.
If you are registered on the old Diverclick platform, you will have received an email where you can register on the new one. If you have accumulated money, don’t worry, as it will remain open for a while so you can spend it.
Go to “Create an account”. Complete the data by entering your corporate email address. If you don’t have one, enter a normal email address and enter the code: ROVI01.
You will receive an email to complete your registration. It may take some time to arrive, depending on the registration traffic.
Take advantage of exclusive offers for ROVI employees. On the website you’ll find discounts in restaurants, supermarkets, cinemas, travel agencies, hotels, fashion, perfumery, homeware… and much more.
Effort, healthy competition and lots of laughter came together on 27 and 28 April at the ROVI Padel Tournament. A total of 42 pairs competed to see who was the best on the courts, dividing the participants into 3 categories according to their level: beginners, intermediate and advanced.
The championship took place at Club Fuencarral A La Par, where 12 padel courts were reserved to make the different phases of the tournament more dynamic. The competition started with a group stage on Saturday 27th, where only the best 4 pairs of each one would go through. On Sunday 28th the final tournament took place, where each pair fought to win their category.
Laboratorios Farmacéuticos ROVI announces the financial results obtained in the first quarter of 2024, that is critically important in establishing the bases for ROVI’s future growth.
The company closed the first quarter of 2024 with operating revenue of 151.2 million euros, EBITDA of 25.9 million euros and a net profit of 15.0 million.
Revenue from the CDMO business decreased 48% to 50.1 million, mainly due to lower revenue from manufacture of the COVID-19 vaccine in comparison with the first quarter of 2023, when ROVI booked higher revenue from production of the ”pandemic” vaccine and lower revenue related to the activities to prepare the plant for production of the vaccine under the agreement with Moderna.
Sales of the heparin franchise (low-molecular-weight heparins and other heparins) fell 8% to 56.3 million euros in the first quarter of 2024, due to a lower volume of orders from partners, since they held a higher level of stocks of these products from the fourth quarter of 2023. Sales of Risperidone ISM® evolved positively upwards to 5.4 million euros in the first quarter of the year, multiplying the 2023 first quarter figure by 2.4. In March 2024, ROVI received FDA approval for the marketing of Risperidone ISM® in the United States to treat schizophrenia in adults.
This is a historic milestone for the company as this is the first of its own product to receive marketing authorisation in the United States, the most important market worldwide for long-acting injectable antipsychotics.
Additionally, in the first quarter of 2024, ROVI approved marketing authorisation for this product in Canada and Australia. Research and development expenses rose 17% to 6.1 million euros and were mainly related to the development of phase 1 of Letrozole LEBE and the development of phase 1 of the new formulation of Risperidone ISM® for a three-monthly injection. Additionally, we were able to decrease operating expenses, excluding R&D and employee benefit expenses, by 11% as the result of an efficient cost containment policy.
Regarding guidance for 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage, although this guidance considers certain factors that could affect the estimates but are difficult to specify at the present time. ROVI is in a new phase of growth and has confidence in the development potential of its specialty pharmaceuticals division and its CDMO business.
